Evolus (NASDAQ:EOLS – Get Free Report) and Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Earnings & Valuation
This table compares Evolus and Nuvectis Pharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $202.09 million | 4.57 | -$61.69 million | ($0.91) | -16.02 |
| Nuvectis Pharma | N/A | N/A | -$22.26 million | ($1.16) | -5.80 |
Nuvectis Pharma has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 0 | 0 | 4 | 0 | 3.00 |
| Nuvectis Pharma | 0 | 0 | 1 | 0 | 3.00 |
Evolus presently has a consensus price target of $23.67, suggesting a potential upside of 62.38%. Nuvectis Pharma has a consensus price target of $21.00, suggesting a potential upside of 212.04%. Given Nuvectis Pharma’s higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Evolus.
Risk and Volatility
Evolus has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.
Institutional and Insider Ownership
90.7% of Evolus shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 6.1% of Evolus shares are owned by company insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Evolus and Nuvectis Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -22.33% | -847.60% | -22.15% |
| Nuvectis Pharma | N/A | -155.80% | -104.02% |
Summary
Nuvectis Pharma beats Evolus on 7 of the 12 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Nuvectis Pharma
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
